Barclays Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...
Teva share price struggles to recover following $6 billion market loss
The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...
Teva holds a pharmaceutical update conference call
Conference call to discuss new data presented for duvakitug (Anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European ...
Seeking Alpha19d
Teva Pharmaceutical snaps six straight sessions of losses
Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 on Wednesday. The company lost over 20% in the preceding six sessions.
Yahoo Finance5d
Is Teva Pharmaceutical (TEVA) Trading at a Discount?
In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...
The Jerusalem Post Blogs25d
Teva falls sharply on disappointing 2025 guidance
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by publishing its fourth quarter and full-year 2024 financial results.
Nasdaq25d
What Analysts Are Saying About Teva Pharmaceutical Indus Stock
Across the recent three months, 4 analysts have shared their insights on Teva Pharmaceutical Indus (NYSE:TEVA), expressing a variety of opinions spanning from bullish to bearish. Summarizing their ...